{
    "id": 8838,
    "name": "Hodgkin's lymphoma, nodular sclerosis",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:8838",
    "evidence": [
        {
            "id": 16703,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with nodular sclerosis Hodgkin's lymphoma demonstrated a partial response lasting almost 6 months following treatment with Domatinostat (4SC-202) (PMID: 30347469; NCT01344707).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4136,
                "therapyName": "Domatinostat",
                "synonyms": null
            },
            "indication": {
                "id": 8838,
                "name": "Hodgkin's lymphoma, nodular sclerosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14729,
                    "pubMedId": 30347469,
                    "title": "Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30347469"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT03712202",
            "title": "Brentuximab Vedotin and Nivolumab in Treating Participants With Early Stage Classic Hodgkin Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 3263,
                    "therapyName": "Brentuximab vedotin + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 6510,
                    "therapyName": "Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine",
                    "synonyms": null
                },
                {
                    "id": 7630,
                    "therapyName": "Bleomycin + Dacarbazine + Doxorubicin + Vinblastine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03907488",
            "title": "Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1476,
                    "therapyName": "Pegfilgrastim",
                    "synonyms": null
                },
                {
                    "id": 6510,
                    "therapyName": "Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine",
                    "synonyms": null
                },
                {
                    "id": 1632,
                    "therapyName": "Filgrastim",
                    "synonyms": null
                },
                {
                    "id": 5296,
                    "therapyName": "Dacarbazine + Doxorubicin + Nivolumab + Vinblastine",
                    "synonyms": null
                }
            ]
        }
    ]
}